Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Healios KK ( (JP:4593) ).
Healios K.K. has entered into a joint research agreement with Kyushu University’s Department of Neurosurgery to study the use of CAR-eNK cells in treating brain tumors. This collaboration aims to evaluate the antitumor effects of these genetically modified cells, potentially enhancing cancer treatment options and reinforcing Healios’ position in the regenerative medicine industry.
The most recent analyst rating on (JP:4593) stock is a Hold with a Yen476.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
HEALIOS K.K. is Japan’s leading clinical stage biotechnology company focusing on regenerative medicine using stem cells. It develops therapies for diseases lacking effective treatments, with a pioneering role in regenerative medicines in Japan. The company utilizes both somatic stem cells and iPS cells, with products like MultiStem® for various conditions and HLCN061 for solid tumors, aiming for global advancement.
Average Trading Volume: 7,401,978
Technical Sentiment Signal: Hold
Current Market Cap: Yen57.59B
For detailed information about 4593 stock, go to TipRanks’ Stock Analysis page.